Articles from RION

RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of Rion Vet, a veterinary biotechnology company advancing platelet-derived exosome-based biologics to address major unmet needs in animal health. The company launches with exclusive global rights to RION’s proprietary Purified Exosome Product (PEP™) platform for veterinary use. Rion Vet anticipates bringing its first product, ePEP-01 for equine musculoskeletal disease, to market after this shelf-stable biologic has shown consistent results in clinical trials over nearly five years of research, discovery and development.

RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond.

RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PEP Biologic™ into Phase 3 clinical development for advanced tissue regeneration and immune-mediated dermatologic indications.

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the addition of Suneet Varma to their leadership team.

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the enrollment of the first patient in its Phase 1b clinical study evaluating Purified Exosome Product™ (PEP™) for the treatment of Knee Osteoarthritis (OA). This milestone highlights RION’s commitment to advancing innovative regenerative therapies that address unmet medical needs.

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, announced today that it has completed patient enrollment in its Phase 2 clinical trial for Purified Exosome Product™ (PEP™) in the treatment of Diabetic Foot Ulcers (DFUs). This milestone marks a significant step forward in the company’s mission to develop cutting-edge therapies addressing chronic wound care.

RION, a clinical-stage regenerative medicine company revolutionizing healthcare through its exosome-based technology, announced today that its Co-Founder, Dr. Atta Behfar, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 10:00 AM PST.

RION, a clinical-stage regenerative medicine company pioneering exosome-based therapeutics, today announced the appointment of five distinguished leaders to its Advisory Board. These new advisors bring decades of expertise in their respective fields, ranging from orthopedic & plastic surgery to infectious diseases, military medicine, biomanufacturing and government health strategy, further positioning RION as a leader in innovative regenerative medicine.

RION, at the forefront of exosome innovation and therapeutic application, has officially commenced a Phase 1b study aimed at assessing the efficacy and safety of Purified Exosome Product™ (PEP™), its exclusive exosome regenerative therapeutic, for the management knee osteoarthritis (Knee OA).

RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™). This event marks a pivotal milestone in evaluating PEP™ as an innovative treatment for chronic conditions such as Diabetic Foot Ulcers (DFUs).

RION, a pioneer in regenerative medicine and exosome technology, has unveiled a major expansion of its manufacturing operations with the inauguration of a state-of-the-art facility in Rochester, Minnesota. In collaboration with Rochester Area Economic Development, Inc., this move represents a significant milestone in RION's mission to bolster its manufacturing capabilities in support of its groundbreaking Rion Aesthetics spin-off and its globally renowned skin and hair brand, (plated)™ Skin Science.

RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).

Rion, a leader in regenerative medicine and exosome technology, today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM. The presentation will showcase Rion's breakthrough developments in platelet-derived regenerative exosome technology and its significant impact across various regenerative medicine therapeutic areas.

RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense. This grant accelerates a critical research initiative aimed at exploring the therapeutic potential of RION's proprietary Purified Exosome Product™ (PEP™) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other challenging pulmonary conditions, which can impact soldiers and veterans exposed to airborne hazards in war zones.

RION, a clinical-stage regenerative medicine company with breakthrough platform technology leveraging platelet-derived exosomes, announces the appointment of Dr. Ballantyne as Chair of the company’s Scientific Advisory Board and Dr. Andrew D. Badley as Chair of the Rion Medical Advisory Board. The company, founded by internationally recognized regenerative medicine experts Drs. Atta Behfar and Andre Terzic, continues to emerge in the regenerative therapeutics utilizing its proprietary manufacturing process and shelf-stable regenerative exosomes for flagship programs in wound healing, cardiology, and orthopedic indications.

RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer.